logo-loader
viewBenitec Biopharma

Benitec Biopharma readies to raise cash

au_australianhundreddollar350_55d26e7e052ed.jpg

Benitec Biopharma (ASX:BLT) has been granted a trading halt by the ASX pending capital raising details.

Benitec has developed a patented gene-silencing technology called ddRNAi, which it has already licensed to other companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.

The halt will remain in place until the opening of trade on Thursday 20th August 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Benitec Biopharma

Price: - -

ASX:BLT
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

4 hours, 13 minutes ago

2 min read